Amarin Corp. plc (AMRN), on Saturday, presented impressive primary results from its Vascepa cardiovascular outcomes trial, dubbed REDUCE-IT, at the 2018 Scientific Sessions of the American Heart Association in Chicago, Illinois. The study findings were simultaneously published in The New England Journal of Medicine.
from RTT - Biotech https://ift.tt/2Ppg1C8
via IFTTT
No comments:
Post a Comment